Ekaterina A Moroz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ekaterina A Moroz has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Valeriy Vladimirovich Breder
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
8 shared publications - Irina A. Dzhanyan
N.N. Blokhin National Medical Research Center of Oncology
7 shared publications - Konstantin K. Laktionov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
7 shared publications - Elena Yu. Antonova
Blokhin National Medical Research Center of Oncology
6 shared publications - Nikolai E. Kudashkin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - Aleksandr N. Polyakov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 128-138
The phenomenon of diffuse infiltrative retinoblastoma with metastatic lesions of the brain and spinal cord. Own clinical observation with a review of the literature
Diffuse infiltrative retinoblastoma (RB) is a rare form of RB, which is the most malignant, first described by N. Ashton in 1958. Its occurrence among all forms of RB according to previously published articles ranges from 2.0 to 4.6 %. The article presents a unique case of diffuse infiltrative RB with extensive damage to the central nervous system, which resulted in remission in a child with a primary diagnosis of the disease at the age of 11 years.
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 128-138
Open AccessThe phenomenon of diffuse infiltrative retinoblastoma with metastatic lesions of the brain and spinal cord. Own clinical observation with a review of the literature
Diffuse infiltrative retinoblastoma (RB) is a rare form of RB, which is the most malignant, first described by N. Ashton in 1958. Its occurrence among all forms of RB according to previously published articles ranges from 2.0 to 4.6 %. The article presents a unique case of diffuse infiltrative RB with extensive damage to the central nervous system, which resulted in remission in a child with a primary diagnosis of the disease at the age of 11 years.
- Open Access
- 19 June 2026
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 13 (2) , 62-70
Association of serum galectin-3 levels in patients with key clinical and morphological characteristics of colorectal cancer
Introduction. Galectins are a family of β-galactoside-binding proteins involved in the regulation of cell adhesion, proliferation, apoptosis, and the immune response, playing a key role in carcinogenesis. Galectin-3 is the only chimeric protein of the galectin family, whose functional activity is determined by its ability to oligomerize. Increased expression of galectin-3 in tumor tissue and its high serum concentration are associated with colorectal cancer (CRC) progression. However, the clinical, morphological, and prognostic significance of serum galectin-3 levels in this disease remains poorly understood. Aim. To analyze the association of galectin-3 levels in the blood serum of patients with key clinical, morphological characteristics and prognosis of CRC. Materials and methods. A total of 210 previously untreated patients with CRC at various stages of the tumor were examined. These patients ranged in age from 31 to 75 years (114 men and 96 women). The control group consisted of 32 healthy donors aged 31 to 67 years (20 women and 12 men). The clinical diagnosis in all patients was confirmed by tumor morphological examination according to the International Histological Classification of Tumors of the Digestive Tract of the World Health Organization (2019). All patients were diagnosed with colon adenocarcinoma of varying degrees of differentiation. Galectin-3 concentrations were determined in serum collected using a standard method before the start of specific treatment using the Human Galectin-3 Quantikine ELISA reagents (RD Systems, USA) according to the manufacturer’s instructions. Measurements were performed on a BEP 2000 Advance automated enzyme-linked immunosorbent assay (Siemens Healthcare Diagnostics, Germany). Marker levels were expressed as nanograms (ng) per 1 ml of serum. The nonparametric Mann–Whitney and Kruskal–Wallis tests were used to compare parameters and analyze their relationships. Overall survival was analyzed using the Kaplan–Meier method and the nonparametric Cox proportional hazards model. Differences and correlations were considered statistically significant at p 0.05. Results. Enzyme-linked immunosorbent assay revealed that baseline pre-treatment serum galectin-3 levels in 210 previously untreated CRC patients ranged widely from 2.6 to 24.7 ng / ml, and the median level (10.7 ng / ml) was statistically significantly higher than that in 32 healthy control donors (8.6 ng / ml) (p = 0.004). ROC analysis data do not support the use of serum galectin-3 levels in the diagnosis of CRC (test sensitivity 39 %, specificity 94 %). The study did not reveal any significant associations between galectin-3 levels and the main clinical and morphological characteristics of CRC. Univariate analysis and Cox regression analysis of galectin-3 levels revealed an unfavorable prognostic significance of this protein in patients with CRC (p = 0.0006 and p = 0.0001, respectively). Conclusion. A statistically significant increase in serum galectin-3 concentrations was observed in patients with colorectal cancer compared to healthy donors. Despite the lack of associations with clinical and morphological characteristics of the tumor, elevated baseline serum galectin-3 levels in patients with colorectal cancer are significantly associated with a poor overall survival prognosis.
- 19 June 2026
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 13 (2) , 62-70
Open AccessAssociation of serum galectin-3 levels in patients with key clinical and morphological characteristics of colorectal cancer
Introduction. Galectins are a family of β-galactoside-binding proteins involved in the regulation of cell adhesion, proliferation, apoptosis, and the immune response, playing a key role in carcinogenesis. Galectin-3 is the only chimeric protein of the galectin family, whose functional activity is determined by its ability to oligomerize. Increased expression of galectin-3 in tumor tissue and its high serum concentration are associated with colorectal cancer (CRC) progression. However, the clinical, morphological, and prognostic significance of serum galectin-3 levels in this disease remains poorly understood. Aim. To analyze the association of galectin-3 levels in the blood serum of patients with key clinical, morphological characteristics and prognosis of CRC. Materials and methods. A total of 210 previously untreated patients with CRC at various stages of the tumor were examined. These patients ranged in age from 31 to 75 years (114 men and 96 women). The control group consisted of 32 healthy donors aged 31 to 67 years (20 women and 12 men). The clinical diagnosis in all patients was confirmed by tumor morphological examination according to the International Histological Classification of Tumors of the Digestive Tract of the World Health Organization (2019). All patients were diagnosed with colon adenocarcinoma of varying degrees of differentiation. Galectin-3 concentrations were determined in serum collected using a standard method before the start of specific treatment using the Human Galectin-3 Quantikine ELISA reagents (RD Systems, USA) according to the manufacturer’s instructions. Measurements were performed on a BEP 2000 Advance automated enzyme-linked immunosorbent assay (Siemens Healthcare Diagnostics, Germany). Marker levels were expressed as nanograms (ng) per 1 ml of serum. The nonparametric Mann–Whitney and Kruskal–Wallis tests were used to compare parameters and analyze their relationships. Overall survival was analyzed using the Kaplan–Meier method and the nonparametric Cox proportional hazards model. Differences and correlations were considered statistically significant at p 0.05. Results. Enzyme-linked immunosorbent assay revealed that baseline pre-treatment serum galectin-3 levels in 210 previously untreated CRC patients ranged widely from 2.6 to 24.7 ng / ml, and the median level (10.7 ng / ml) was statistically significantly higher than that in 32 healthy control donors (8.6 ng / ml) (p = 0.004). ROC analysis data do not support the use of serum galectin-3 levels in the diagnosis of CRC (test sensitivity 39 %, specificity 94 %). The study did not reveal any significant associations between galectin-3 levels and the main clinical and morphological characteristics of CRC. Univariate analysis and Cox regression analysis of galectin-3 levels revealed an unfavorable prognostic significance of this protein in patients with CRC (p = 0.0006 and p = 0.0001, respectively). Conclusion. A statistically significant increase in serum galectin-3 concentrations was observed in patients with colorectal cancer compared to healthy donors. Despite the lack of associations with clinical and morphological characteristics of the tumor, elevated baseline serum galectin-3 levels in patients with colorectal cancer are significantly associated with a poor overall survival prognosis.
- Open Access
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 36-43
Effectiveness and safety of Atezolizumab and Bevacizumab as conversion therapy for unresectable or advanced HCC in real-world clinical practice in Russia: Multicenter retrospective observational study
Introduction . Hepatocellular carcinoma (HCC) is a rare disorder in Russia, but its 1-year mortality rate is comparable to that of pancreatic cancer, reflecting its high aggressiveness and poor prognosis. Atezolizumab combined with Bevacizumab (A + B) is the standard of care for hepatocellular carcinoma (HCC) with a high objective response rate (ORR). Aim . To evaluate the potential of systemic immunotargeted therapy (ITT) with a combination of A+B to downstage advanced HCC and convert nonsurgical candidates into eligible candidates for transplant, i.e. the state that meets the criteria for orthotopic liver transplantation (OLT), and to explore the safety after ITT. Materials and methods . A real-world retrospective study to evaluate the efficacy of A+B therapy in converting patients with advanced HCC to a state amenable to surgical treatment and outcomes of OLT was conducted. The results of 12 patients with BCLC-B3 and C hepatocellular carcinoma who received A + B therapy at standard doses from January 1, 2019, to May 2024 at the Russian cancer center and the transplant center were presented. The effectiveness of therapy, the median number of ITT cycles administered, changes in the alpha-fetoprotein (AFP) levels, the safety profile, and progression-free survival (PFS) and overall survival (OS) rates were assessed. Results . The median number of ITT cycles administered was 8. The median waiting period for OLT after completion of ITT was up to 2 months. The median alpha-fetoprotein (AFP) level decreased from 1975 to 8.2 ng/mL. A complete response was observed in 1 case (8.3%), HCC stage was downstaged to Milan Criteria in 2 cases (16.7%), and to University of California, San Francisco (UCSF) Criteria in 3 cases (25%). The results demonstrated 1-, 3-, and 5-year overall survival rates of 91.7%, 73%, and 73%, respectively. The mortality rate was 33.3%, or 4 out of 12 cases, with 2 of these deaths not being associated with tumor progression. Conclusion . In our retrospective study, A + B systemic therapy demonstrated high efficacy and safety and may represent a promising treatment option for conversion therapy of inoperable HCC.
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 36-43
Open AccessEffectiveness and safety of Atezolizumab and Bevacizumab as conversion therapy for unresectable or advanced HCC in real-world clinical practice in Russia: Multicenter retrospective observational study
Introduction . Hepatocellular carcinoma (HCC) is a rare disorder in Russia, but its 1-year mortality rate is comparable to that of pancreatic cancer, reflecting its high aggressiveness and poor prognosis. Atezolizumab combined with Bevacizumab (A + B) is the standard of care for hepatocellular carcinoma (HCC) with a high objective response rate (ORR). Aim . To evaluate the potential of systemic immunotargeted therapy (ITT) with a combination of A+B to downstage advanced HCC and convert nonsurgical candidates into eligible candidates for transplant, i.e. the state that meets the criteria for orthotopic liver transplantation (OLT), and to explore the safety after ITT. Materials and methods . A real-world retrospective study to evaluate the efficacy of A+B therapy in converting patients with advanced HCC to a state amenable to surgical treatment and outcomes of OLT was conducted. The results of 12 patients with BCLC-B3 and C hepatocellular carcinoma who received A + B therapy at standard doses from January 1, 2019, to May 2024 at the Russian cancer center and the transplant center were presented. The effectiveness of therapy, the median number of ITT cycles administered, changes in the alpha-fetoprotein (AFP) levels, the safety profile, and progression-free survival (PFS) and overall survival (OS) rates were assessed. Results . The median number of ITT cycles administered was 8. The median waiting period for OLT after completion of ITT was up to 2 months. The median alpha-fetoprotein (AFP) level decreased from 1975 to 8.2 ng/mL. A complete response was observed in 1 case (8.3%), HCC stage was downstaged to Milan Criteria in 2 cases (16.7%), and to University of California, San Francisco (UCSF) Criteria in 3 cases (25%). The results demonstrated 1-, 3-, and 5-year overall survival rates of 91.7%, 73%, and 73%, respectively. The mortality rate was 33.3%, or 4 out of 12 cases, with 2 of these deaths not being associated with tumor progression. Conclusion . In our retrospective study, A + B systemic therapy demonstrated high efficacy and safety and may represent a promising treatment option for conversion therapy of inoperable HCC.
- Open Access
- 1 August 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (2) , 90-95
Clinical view on pathomorphological risk factors after initial enucleation of the eye for retinoblastoma. Literature review
Retinoblastoma (RB) is the most common malignant tumor of the eye found in pediatric practice. Currently, in developed countries, the overall survival rate is approaching 100 % with a high rate of eye preservation up to 90 %, but such a treatment method as enucleation remains relevant today. The study of prognostic morphological factors in eyes removed after enucleation has been the subject of study for several decades in order to optimize adjuvant therapy. On the one hand, to intensify treatment to prevent relapse of RB, on the other hand, to refuse chemotherapy to avoid “overtreatment” of the patient.Our article presents an analysis of the experience of different countries in determining morphological risk factors that influence the appointment of adjuvant chemotherapy after primary enucleation.
- 1 August 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (2) , 90-95
Open AccessClinical view on pathomorphological risk factors after initial enucleation of the eye for retinoblastoma. Literature review
Retinoblastoma (RB) is the most common malignant tumor of the eye found in pediatric practice. Currently, in developed countries, the overall survival rate is approaching 100 % with a high rate of eye preservation up to 90 %, but such a treatment method as enucleation remains relevant today. The study of prognostic morphological factors in eyes removed after enucleation has been the subject of study for several decades in order to optimize adjuvant therapy. On the one hand, to intensify treatment to prevent relapse of RB, on the other hand, to refuse chemotherapy to avoid “overtreatment” of the patient.Our article presents an analysis of the experience of different countries in determining morphological risk factors that influence the appointment of adjuvant chemotherapy after primary enucleation.
- Open Access
- 25 July 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 162-166
Experience with the use of nivolumab and ipilimumab in metastatic fibrolamellar liver carcinoma
Fibrolamellar hepatocellular carcinoma is a rare primary liver tumor with no known risk factors, which occurs in 1–7% of cases of all hepatocellular carcinoma. The disease occurs mainly in adolescents, as an accidental finding or when symptoms appear already during the metastatic process. The main method of treatment with proven efficacy for localized fibrolamellar hepatocellular carcinoma is surgical. The experience of using radiation therapy and transarterial chemoembolization is contradictory and needs additional study. The option of preferred drug antitumor treatment is not fully clear, and the search for effective therapy regimens and potential targets specific to this form of hepatocellular carcinoma is relevant and requires further study. Considering the rarity of the pathology, the world literature presents data on the treatment of small groups of patients and clinical cases of successful use of a number of medicinal antitumor regimens. However, the data are contradictory. The literature describes isolated clinical cases of successful use of immunotherapy in patients with fibrolamellar hepatocellular carcinoma, requiring further detailed study. Using the example of this clinical case, we have shown the successful long-term use of combined immunotherapy in a patient with fibrolamellar liver carcinoma.
- 25 July 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 162-166
Open AccessExperience with the use of nivolumab and ipilimumab in metastatic fibrolamellar liver carcinoma
Fibrolamellar hepatocellular carcinoma is a rare primary liver tumor with no known risk factors, which occurs in 1–7% of cases of all hepatocellular carcinoma. The disease occurs mainly in adolescents, as an accidental finding or when symptoms appear already during the metastatic process. The main method of treatment with proven efficacy for localized fibrolamellar hepatocellular carcinoma is surgical. The experience of using radiation therapy and transarterial chemoembolization is contradictory and needs additional study. The option of preferred drug antitumor treatment is not fully clear, and the search for effective therapy regimens and potential targets specific to this form of hepatocellular carcinoma is relevant and requires further study. Considering the rarity of the pathology, the world literature presents data on the treatment of small groups of patients and clinical cases of successful use of a number of medicinal antitumor regimens. However, the data are contradictory. The literature describes isolated clinical cases of successful use of immunotherapy in patients with fibrolamellar hepatocellular carcinoma, requiring further detailed study. Using the example of this clinical case, we have shown the successful long-term use of combined immunotherapy in a patient with fibrolamellar liver carcinoma.
- 4 July 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (2)
Radiosurgical Maintenance of Indeterminate Proximal Biliary Stricture. Clinical Observation
The paper presents a case of an indeterminate proximal biliary stricture in a patient who admitted to the N.N. Blokhin National Medical Research Center of Oncology with a referral diagnosis of Klatskin tumor and 6 years earlier had undergone cholecystectomy for calculous cholecystitis complicated by Mirizzi syndrome. The authors highlight the difficulties of biliary lesion differentiation as well as the importance of anamnestic, clinical, imaging, laboratory and morphological data synthesis with the emphasis on percucationous endobiliary interventions to establish the etiology of the disease.
- 4 July 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (2)
Radiosurgical Maintenance of Indeterminate Proximal Biliary Stricture. Clinical Observation
The paper presents a case of an indeterminate proximal biliary stricture in a patient who admitted to the N.N. Blokhin National Medical Research Center of Oncology with a referral diagnosis of Klatskin tumor and 6 years earlier had undergone cholecystectomy for calculous cholecystitis complicated by Mirizzi syndrome. The authors highlight the difficulties of biliary lesion differentiation as well as the importance of anamnestic, clinical, imaging, laboratory and morphological data synthesis with the emphasis on percucationous endobiliary interventions to establish the etiology of the disease.
- Open Access
- 17 January 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 22,p. 20-28
Advisory board resolution: The role of the adjuvant atezolizumab plus bevacizumab in patients with hepatocellular carcinoma at high risk of recurrence following surgical resection or ablation
MEETING DATE: July 7, 2023ITEMS ON THE AGENDA:1. The role of the adjuvant atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC) at high risk of recurrence following surgical resection or ablation. Profile of the patient who will benefit the most from this therapy.2. To evaluate the prospects for therapeutic options for patients with early HCC in Russia.Liver cancer remains a public health concern globally, with an increasing trend in the number of incident cases worldwide. Early, precise diagnosis and timely treatment contribute to the improvement in overall and relapse-free survival. It is important that the entire arsenal of local treatments (resection, ablation and liver transplantation) can be applied in cases when HCC is detected at a very early and early stage of the disease. Tumour recurrence after surgical treatment or ablation is a complex and underexplored problem in the treatment of patients with HCC. Many factors that can predict the risk of relapse after surgical treatment have been described: tumour size >5 cm, >3 foci, micro- or macrovascular (Vp1-2) invasion, poor degree of tumour differentiation (G3-4). Our advisory board tried to identify the most important risk factors for early relapse, and to determine the role and impact of the results of the first positive clinical trial focused on the issue of early HCC, IMbrave050: a phase 3 trial of adjuvant atezolizumab + bevacizumab vs active surveillance in patients with HCC at high risk of disease recurrence following resection or ablatio.
- 17 January 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 22,p. 20-28
Open AccessAdvisory board resolution: The role of the adjuvant atezolizumab plus bevacizumab in patients with hepatocellular carcinoma at high risk of recurrence following surgical resection or ablation
MEETING DATE: July 7, 2023ITEMS ON THE AGENDA:1. The role of the adjuvant atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC) at high risk of recurrence following surgical resection or ablation. Profile of the patient who will benefit the most from this therapy.2. To evaluate the prospects for therapeutic options for patients with early HCC in Russia.Liver cancer remains a public health concern globally, with an increasing trend in the number of incident cases worldwide. Early, precise diagnosis and timely treatment contribute to the improvement in overall and relapse-free survival. It is important that the entire arsenal of local treatments (resection, ablation and liver transplantation) can be applied in cases when HCC is detected at a very early and early stage of the disease. Tumour recurrence after surgical treatment or ablation is a complex and underexplored problem in the treatment of patients with HCC. Many factors that can predict the risk of relapse after surgical treatment have been described: tumour size >5 cm, >3 foci, micro- or macrovascular (Vp1-2) invasion, poor degree of tumour differentiation (G3-4). Our advisory board tried to identify the most important risk factors for early relapse, and to determine the role and impact of the results of the first positive clinical trial focused on the issue of early HCC, IMbrave050: a phase 3 trial of adjuvant atezolizumab + bevacizumab vs active surveillance in patients with HCC at high risk of disease recurrence following resection or ablatio.
- 23 April 2023
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 6,p. 108-113
Laparoscopic distal pancreatectomy for portal annular pancreas
Portal annular pancreas is a little-known anatomical variant of annular pancreas. In these patients, pancreatic parenchyma encircles the portal vein annularly. This anomaly is associated with high risk of postoperative pancreatic fistula in pancreatic surgery. Considering small incidence of anomaly and characteristics of surgery, we describe laparoscopic distal pancreatectomy with preservation of spleen and splenic vessels in a patient with solid pseudopapillary tumor combined with portal annular pancreas. A 33-year-old woman underwent laparoscopic surgery for cystic-solid pancreatic tumor. Spleen-sparing distal pancreatectomy was performed. Portal annular pancreas was visualized intraoperatively and confirmed retrospectively after analysis of MR data. Ventral and dorsal parts of portal annular pancreas were transected using stapler device. Pancreatic fistula developed in postoperative period. The patient was discharged after 6 days with a drainage tube. Surgeons need to be aware of portal annular pancreas. This anomaly increases the risk of postoperative fistula. Transection of ventral and dorsal parts of annular pancreas using stapler device is the most acceptable option to reduce the risk of postoperative fistula.
- 23 April 2023
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 6,p. 108-113
Laparoscopic distal pancreatectomy for portal annular pancreas
Portal annular pancreas is a little-known anatomical variant of annular pancreas. In these patients, pancreatic parenchyma encircles the portal vein annularly. This anomaly is associated with high risk of postoperative pancreatic fistula in pancreatic surgery. Considering small incidence of anomaly and characteristics of surgery, we describe laparoscopic distal pancreatectomy with preservation of spleen and splenic vessels in a patient with solid pseudopapillary tumor combined with portal annular pancreas. A 33-year-old woman underwent laparoscopic surgery for cystic-solid pancreatic tumor. Spleen-sparing distal pancreatectomy was performed. Portal annular pancreas was visualized intraoperatively and confirmed retrospectively after analysis of MR data. Ventral and dorsal parts of portal annular pancreas were transected using stapler device. Pancreatic fistula developed in postoperative period. The patient was discharged after 6 days with a drainage tube. Surgeons need to be aware of portal annular pancreas. This anomaly increases the risk of postoperative fistula. Transection of ventral and dorsal parts of annular pancreas using stapler device is the most acceptable option to reduce the risk of postoperative fistula.
- Open Access
- 15 December 2022
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 27 (4) , 41-46
Resecting liver segments VII–VIII without reconstructing the right hepatic vein
Aim. To improve outcomes of treatment for neoplasms in segments VII-VIII of the liver adjacent to the main stem of the right hepatic vein and/or to its forming large branches.Materials and methods. In the period of 2016–2022, the resection of segments VII and/or VIII of the liver and the right hepatic vein, as well as its forming branches without reconstruction was performed in 24 patients. Surgical indications were liver metastases of colorectal cancer in 15 cases, hepatocellular cancer (cholangiocarcinoma) in six cases, angiomyolipoma in one case, uterine cancer metastases in one case and primary retroperitoneal tumor metastases in one case. Minor liver resections were additionally performed in 11 cases. Results. There were no intraoperative signs of impaired venous drainage. After surgery bile in the drains was detected in three patients, and a biliary fistula was formed in one case. No other complications were identified. No fatalities were registered after surgery. The late postoperative period revealed no specific complications related to a disturbance of venous drainage through the right hepatic vein.Conclusion. Existing and emerging collaterals can provide adequate venous drainage to the middle hepatic vein, short hepatic veins after resection of liver segments VII and VIII with resection of the right hepatic vein stem and its forming branches without reconstruction, even if the lower right hepatic vein is missing, and without complete obstruction of the right hepatic vein before surgery.
- 15 December 2022
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 27 (4) , 41-46
Open AccessResecting liver segments VII–VIII without reconstructing the right hepatic vein
Aim. To improve outcomes of treatment for neoplasms in segments VII-VIII of the liver adjacent to the main stem of the right hepatic vein and/or to its forming large branches.Materials and methods. In the period of 2016–2022, the resection of segments VII and/or VIII of the liver and the right hepatic vein, as well as its forming branches without reconstruction was performed in 24 patients. Surgical indications were liver metastases of colorectal cancer in 15 cases, hepatocellular cancer (cholangiocarcinoma) in six cases, angiomyolipoma in one case, uterine cancer metastases in one case and primary retroperitoneal tumor metastases in one case. Minor liver resections were additionally performed in 11 cases. Results. There were no intraoperative signs of impaired venous drainage. After surgery bile in the drains was detected in three patients, and a biliary fistula was formed in one case. No other complications were identified. No fatalities were registered after surgery. The late postoperative period revealed no specific complications related to a disturbance of venous drainage through the right hepatic vein.Conclusion. Existing and emerging collaterals can provide adequate venous drainage to the middle hepatic vein, short hepatic veins after resection of liver segments VII and VIII with resection of the right hepatic vein stem and its forming branches without reconstruction, even if the lower right hepatic vein is missing, and without complete obstruction of the right hepatic vein before surgery.
- Open Access
- 6 December 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 22,p. 130-135
Optimal choice of drug antitumor treatment in patients with Fibrolamellar liver carcinoma
Introduction. Fibrolamellar hepatocellular carcinoma (FlC) is a rare subtype of hepatocellular carcinoma (HCC). Drug antitumor treatment of FlC has not been studied sufficiently due to the rarity of the pathology and requires further research to choose an effective treatment.Aim. The choice of effective drug antitumor treatment in patients with fibrolamellar liver carcinoma.Materials and methods. The retrospective study included 31 patients with FlC who received drug antitumor therapy at the N.N. Blokhin National Research Center of Oncology of the Ministry of Health of the Russian Federation in the period from 2005 to 2020. The patients were divided into comparison groups: “targeted therapy” (mainly sorafenib), “chemotherapy” (mainly gemcitabine + cisplatin). A comparative intergroup analysis of the effectiveness of drug antitumor treatment in the 1st and 2nd lines of therapy was carried out. Adjuvant chemotherapy was evaluated for time without progression. The correlation of the number of treatment lines in the anamnesis with the prognosis of the disease was also evaluated.Results. Analysis of the effect of adjuvant therapy on relapse-free survival did not prove significant differences between the comparison groups (p = 0.112; log-rank test). Therapy with multikinase inhibitors (mainly sorafenib) allows to achieve a better time without progression compared to chemotherapy (mainly gemcitabine + cisplatin / oxaliplatin) (p = 0.000; log-rank test) in patients in the 1st line of FlC treatment. OS did not significantly differ between the groups (p = 0.417; log-rank test). In line 2, time without progression in patients receiving targeted therapy (p = 0.042; log-rank test) is higher compared to patients receiving chemotherapy in line 2. A longer duration of OV was recorded in the groups of patients who underwent 2 lines of drug antitumor treatment and in the group of 3 or more lines compared with the use of only 1st line of treatment (p = 0.024) and (p = 0.003), respectively.Conclusion. The results of the work demonstrate an advantage in the appointment of targeted therapy as the 1st and 2nd lines of drug antitumor treatment, while the appointment of chemotherapy remains a less prognostically favorable option. Adjuvant therapy administration did not demonstrate a statistically significant difference in relapse-free survival.
- 6 December 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 22,p. 130-135
Open AccessOptimal choice of drug antitumor treatment in patients with Fibrolamellar liver carcinoma
Introduction. Fibrolamellar hepatocellular carcinoma (FlC) is a rare subtype of hepatocellular carcinoma (HCC). Drug antitumor treatment of FlC has not been studied sufficiently due to the rarity of the pathology and requires further research to choose an effective treatment.Aim. The choice of effective drug antitumor treatment in patients with fibrolamellar liver carcinoma.Materials and methods. The retrospective study included 31 patients with FlC who received drug antitumor therapy at the N.N. Blokhin National Research Center of Oncology of the Ministry of Health of the Russian Federation in the period from 2005 to 2020. The patients were divided into comparison groups: “targeted therapy” (mainly sorafenib), “chemotherapy” (mainly gemcitabine + cisplatin). A comparative intergroup analysis of the effectiveness of drug antitumor treatment in the 1st and 2nd lines of therapy was carried out. Adjuvant chemotherapy was evaluated for time without progression. The correlation of the number of treatment lines in the anamnesis with the prognosis of the disease was also evaluated.Results. Analysis of the effect of adjuvant therapy on relapse-free survival did not prove significant differences between the comparison groups (p = 0.112; log-rank test). Therapy with multikinase inhibitors (mainly sorafenib) allows to achieve a better time without progression compared to chemotherapy (mainly gemcitabine + cisplatin / oxaliplatin) (p = 0.000; log-rank test) in patients in the 1st line of FlC treatment. OS did not significantly differ between the groups (p = 0.417; log-rank test). In line 2, time without progression in patients receiving targeted therapy (p = 0.042; log-rank test) is higher compared to patients receiving chemotherapy in line 2. A longer duration of OV was recorded in the groups of patients who underwent 2 lines of drug antitumor treatment and in the group of 3 or more lines compared with the use of only 1st line of treatment (p = 0.024) and (p = 0.003), respectively.Conclusion. The results of the work demonstrate an advantage in the appointment of targeted therapy as the 1st and 2nd lines of drug antitumor treatment, while the appointment of chemotherapy remains a less prognostically favorable option. Adjuvant therapy administration did not demonstrate a statistically significant difference in relapse-free survival.